Investor News

Nick Stone
Senior Vice President
Investor Relations

Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
T +49 6172 608-2485
nick.stone@fresenius.com
www.fresenius.com

September 7, 2026

Fresenius expands Medical Nutrition Portfolio with new real-food-based[1] enteral nutrition concept

NutriChef launches in several European markets and combines real food ingredients[1] with the consistency and nutritional completeness of medical nutrition

- The launch of NutriChef, the fifth product launch within Fresenius' Medical Nutrition portfolio in 2026, reflects the company's commitment to patient-centered innovation-led growth and further strengthens its portfolio in nutritional care
- NutriChef expands Fresenius' enteral nutrition offering with a real-food-based concept designed around the needs of patients, caregivers, and healthcare professionals
- Medical Nutrition is an attractive healthcare market supported by aging populations, increased demand for homecare, and growing awareness of the role of nutrition in patient care

Fresenius announced today the launch of NutriChef, a new enteral nutrition option that combines real food ingredients[1] such as fruit and vegetables while maintaining the nutritional completeness required for medical nutrition, in Germany, Switzerland, Norway, Netherlands, Denmark, and Sweden.

The product is designed to bridge the gap between conventional formula-based tube feeding and the familiarity associated with real meals and home-prepared foods. Available in three nutritionally complete, meal-inspired varieties[2], they contain ingredients derived from 21 different plants and more than 75 percent real food ingredients, including water and oils[1]. The product provides high energy and protein as well as a blend of soluble and insoluble fibers.

"For many patients, the challenge is not only getting the nutrition they need. It is adapting to a new reality," said Sebastien Guery, Executive Vice President Business Unit Medical Nutrition. "NutriChef responds to that need by combining familiar foods into enteral feeding with the safety, consistency and nutritional standards required in medical care. It is also a testament to the innovation-led growth of Fresenius, reflecting our ability to translate evolving patient needs into differentiated innovations and meaningful portfolio expansion."

Developed for patients who require enteral nutrition, the new offering combines familiar food-based ingredients with the reliability and quality standards expected from medical nutrition. It offers patients, caregivers, and healthcare professionals an additional option that brings familiar food concepts into nutritional care.

As populations age and more care shifts beyond the hospital into outpatient and homecare settings, nutritional support is becoming increasingly important across healthcare systems. Fresenius continues to see strong long-term demand in Medical Nutrition, supported by demographic trends, growing awareness of disease-related malnutrition, and the need for solutions that fit into patients' daily lives.

As the fifth addition to Fresenius' Medical Nutrition portfolio introduced in 2026, NutriChef underscores the company's continued investment in nutritional care across enteral and parenteral nutrition, the company continues to expand access to high-quality medical nutrition while addressing practical challenges faced by patients, caregivers, and healthcare professionals. As part of #FutureFresenius, the company continues to strengthen its portfolio with differentiated solutions that address evolving patient needs.

NutriChef is a food for special medical purposes for the dietary management of disease-related malnutrition, to be used under medical supervision. Product availability may vary by market.
NutriChef is essentially designed as an adult medical nutrition product, with limited, controlled use in:

- *children >3 years (restricted)*
- *adolescents (possible full use only with medical supervision)*

References

[1] Fresenius Kabi. *NutriChef Ingredient List and Product Specification*. Fresenius Kabi; 2026.
[2] Fresenius Kabi Market Research; Real Food & Tube Feeding Insights Study, 2022.

About Fresenius
Fresenius SE & Co. KGaA (XETR: FRE; OTCM: FSNUY) is a global healthcare company headquartered in Bad Homburg vor der Höhe, Germany. In the full-year 2025, Fresenius generated €22.6 billion (excluding special items) in annual revenue. Fresenius employs more than 178,000 people. The Fresenius Group comprises the operating companies Fresenius Kabi and Fresenius Helios as well as an investment in the separately listed Fresenius Medical Care AG. With around 140 hospitals, 330 outpatient facilities and 300 occupational risk prevention centres, Fresenius Helios is the leading private hospital operator in Germany and Spain, treating around 27 million patients every year. Fresenius Kabi's product portfolio touches the lives of 450 million patients annually and includes a range of highly complex biopharmaceuticals, clinical nutrition, medical technology, and intravenous generic drugs and fluids. Fresenius was established in 1912 by the Frankfurt pharmacist Dr. Eduard Fresenius. After his death, Else Kröner took over management of the company in 1952. She laid the foundations for a global enterprise that today pursues the goal of improving people's health. The largest shareholder is the non-profit Else Kröner Fresenius Foundation, which is dedicated to advancing medical research and supporting humanitarian projects.

For more information, visit fresenius.com and follow Fresenius Investor Relations on LinkedIn.

About Fresenius Medical Care
Fresenius Medical Care AG is an independent, separately listed company (XETR: FME; NYSE: FMS), in which Fresenius SE & Co. KGaA holds a financial investment of approximately 25%; Fresenius Medical Care's results are not consolidated in the Fresenius Group's revenue and earnings.

Forward-Looking Statements
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Correspondence Address

Fresenius SE & Co. KGaA	**Fresenius Management SE**
Registered Office	**Registered Office**
Bad Homburg, Germany	Bad Homburg, Germany
Commercial Register	**Commercial Register**
Amtsgericht Bad Homburg, HRB 11852	Amtsgericht Bad Homburg, HRB 11673

Chairman of the Supervisory Board
Wolfgang Kirsch

Management Board
Michael Sen (Chairman), Pierluigi Antonelli,
Sara Hennicken, Dr. Michael Moser,
Dr. Christian Pawlu

Chairman of the Supervisory Board
Wolfgang Kirsch

Securities Information
Fresenius SE & Co. KGaA is listed on the Frankfurt Stock Exchange and is a member of the DAX 40 index. The shares are traded on Xetra, the electronic trading venue of Deutsche Börse, under the ticker FRE.
ISIN: DE000FRE5EN2 ● German Securities Code: FRE5EN

American Depository Receipts
Fresenius SE & Co. KGaA maintains a sponsored Level I American Depositary Receipt programme, traded over the counter in the United States on the OTC Markets platform under the ticker FSNUY, at a ratio of four American Depositary Receipts to one ordinary share. Depositary bank: J.P. Morgan Chase Bank N.A.
ISIN: US35804M1053 ● CUSIP: 35804M105

Contacts
For Media contacts, click here, and to contact Investor Relations, click here.

●●● **End** ●●●
